April 09, 2026

Tony Hyman starts as EMBL Director General

Tony Hyman starts as EMBL Director General

Former EMBL group leader returns to lead the organisation’s six sites at a time of change and opportunity in life sciences

Tony Hyman starts as EMBL’s new Director General on 31 March 2026. Credit: Sven Döring

EMBL welcomes its new Director General, Tony Hyman, who will take up the mandate of leading EMBL’s six sites as the organisation enters its next phase.

Hyman succeeds Interim Director Ewan Birney, who assumed leadership following the death of Interim Director General Peer Bork in January. Together, they led EMBL after former Director General Edith Heard departed to become Director and Chief Executive of the Francis Crick Institute in London.

Hyman has had a long-standing relationship with EMBL, having served as a group leader and visiting senior scientist at EMBL Heidelberg from 1993 to 1999. He is also one of four founding directors of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and holds a professorship of Molecular Biology at Technische Universität Dresden. His research focuses on the role of biological condensates and phase separation in health and disease.

“This is a moment when biology is changing rapidly,” said Hyman. “Advances in imaging, large-scale data generation, and artificial intelligence are reshaping how we study living systems. EMBL has played an important role in previous periods of change, and I look forward to working with colleagues across the organisation as it enters this next phase.”

Our latest News

discover more
Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Effective June 1, 2026, the Supervisory Board has appointed Hanns-Peter Knaebel, Chairman of the Executive Board, to serve as Chief Medical Officer. This move will ensure that the dynamic phase of medical strategy development and transformation within the group is overseen and managed centrally by the full Executive Board. Full Text in German below. Professor […]

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

HEILBRONN, Germany, May 14, 2026 – ProtaGene today announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end testing solution across the entire biopharmaceutical product lifecycle, from early-stage development through GMP release testing. ProtaGene’s expertise in advanced protein […]

Universität Heidelberg Successful with Application for Collaborative Research Centre

Universität Heidelberg Successful with Application for Collaborative Research Centre

DFG funds extended CRC with approximately 17.4 million euros Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG) with a grant application for a major research consortium: The Collaborative Research Centre “Molecular Circuits of Heart Disease” (CRC 1550), based at the Medical Faculty Heidelberg, is entering a second […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp